(June 14 16:15) Forbes.com
In 2014 ResTORbio spun off out of Novartis and went public to try a longevity drug as a vaccine-potentiating agent in the elderly. The company was led by Dr. Joan Mannick, a physician with deep interest in aging. The trial failed in Phase III providing valuable experience, and her work continues.
You can find the original article
here
